Phathom Pharmaceuticals PHAT
$4.66 −$0.42 (-8.27%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.66 0.00%
Open$4.93
Prev close$5.08
Day range$4.62 – $5.15
Volume1.33M
Market cap$378.82M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$84.72M+71.1% YoY
Operating profit-$85,000.00+99.4% YoY
Net profit-$13.90M+53.6% YoY
Diluted EPS-$0.16+61.0% YoY
Free cash flow$1.73M+112.2% YoY
Operating cash flow$1.84M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin80.7%
Operating margin-9.3%
Net margin-30.2%
Return on assets-28.4%
Current ratio1.76
Liabilities / assets200.8%
Cash & investments$184.56M
Total debt$167.28M
Net cash (debt)$17.27M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $84.72M | $74.27M | $58.30M | $175.11M | $57.58M |
| Total Operating Revenue | $84.72M | $74.27M | $58.30M | $175.11M | $57.58M |
| Cost of Revenue | $18.37M | $15.10M | $12.00M | $22.60M | $7.65M |
| Gross Profit | $66.36M | $59.18M | $46.31M | $152.51M | $49.94M |
| Operating Expense | $66.44M | $63.14M | $61.78M | $312.50M | $55.86M |
| Selling and Admin Expenses | $57.70M | $55.33M | $54.01M | $279.72M | $48.37M |
| Research & Development | $8.75M | $7.81M | $7.77M | $32.78M | $7.49M |
| Operating Profit | -$85,000.00 | -$3.97M | -$15.48M | -$159.99M | -$5.93M |
| Net Non-Operating Interest Income (Expense) | -$13.79M | -$13.59M | -$14.06M | -$61.07M | -$15.22M |
| Non-Operating Interest Income | $1.60M | $1.51M | $1.74M | $7.04M | $1.20M |
| Non-Operating Interest Expense | $15.39M | $15.10M | $15.80M | $68.12M | $16.42M |
| Other Income (Expense) | -$25,000.00 | -$24,000.00 | -$831,000.00 | -$190,000.00 | -$5,000.00 |
| Other Non-Operating Income (Expenses) | -$25,000.00 | -$24,000.00 | -$831,000.00 | -$190,000.00 | -$5,000.00 |
| Pretax Profit | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Net Profit | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Profit from Continuing Operations | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Net Income to Parent Company | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Net Income to Common Stockholders | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Basic EPS | -$0.16 | -$0.21 | -$0.37 | -$3.03 | -$0.29 |
| Diluted EPS | -$0.16 | -$0.21 | -$0.37 | -$3.03 | -$0.29 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $345.02M | $327.08M | $305.12M | $259.15M | $259.15M |
| Total Current Assets | $308.01M | $295.92M | $276.57M | $228.97M | $228.97M |
| Cash and Cash Equivalents & Short-Term Investments | $184.56M | $182.48M | $180.90M | $129.97M | $129.97M |
| -Cash and Cash Equivalents | $184.56M | $182.48M | $180.90M | $129.97M | $129.97M |
| Receivables | $107.60M | $97.42M | $80.72M | $78.13M | $78.13M |
| -Accounts Receivable | $107.60M | $97.42M | $80.72M | $78.13M | $78.13M |
| Inventory | $7.63M | $7.71M | $6.51M | $5.52M | $5.52M |
| Other Current Assets | $8.22M | $8.30M | $8.44M | $15.35M | $15.35M |
| Total Non-Current Assets | $37.01M | $31.16M | $28.55M | $30.18M | $30.18M |
| Net PPE | $3.25M | $3.38M | $3.52M | $3.67M | $3.67M |
| -Gross PPE | $3.25M | $3.38M | $3.52M | $7.14M | $7.14M |
| Other Non-Current Assets | $33.76M | $27.78M | $25.03M | $26.51M | $26.51M |
| Total Liabilities | $692.66M | $671.35M | $642.08M | $697.32M | $697.32M |
| Total Current Liabilities | $174.90M | $153.78M | $125.04M | $132.04M | $132.04M |
| Payables | $11.11M | $5.36M | $6.37M | $4.98M | $4.98M |
| -Accounts Payable | $11.11M | $5.36M | $6.37M | $4.98M | $4.98M |
| Current Accrued Expenses | $108.21M | $97.16M | $75.78M | $76.82M | $76.82M |
| Short-Term Debt and Capital Lease Obligation | $673,000.00 | $670,000.00 | $667,000.00 | $648,000.00 | $648,000.00 |
| -Current Capital Lease Obligation | $673,000.00 | $670,000.00 | $667,000.00 | $648,000.00 | $648,000.00 |
| Other Current Liabilities | $40.52M | $37.28M | $33.02M | $34.75M | $34.75M |
| Total Non-Current Liabilities | $517.76M | $517.57M | $517.03M | $565.27M | $565.27M |
| Long Term Debt and Capital Lease Obligation | $167.28M | $166.44M | $165.64M | $211.15M | $211.15M |
| -Long Term Debt | $165.54M | $164.59M | $163.68M | $209.09M | $209.09M |
| -Long Term Capital Lease Obligation | $1.74M | $1.86M | $1.96M | $2.07M | $2.07M |
| Other Non-Current Liabilities | $350.47M | $351.13M | $351.40M | $354.12M | $354.12M |
| Total Equity | -$347.64M | -$344.27M | -$336.96M | -$438.17M | -$438.17M |
| Stockholders' Equity | -$347.64M | -$344.27M | -$336.96M | -$438.17M | -$438.17M |
| Capital Stock | $8,000.00 | $8,000.00 | $7,000.00 | $6,000.00 | $6,000.00 |
| -Common Stock | $8,000.00 | $8,000.00 | $7,000.00 | $6,000.00 | $6,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.20B | $1.19B | $1.18B | $1.05B | $1.05B |
| Retained Earnings | -$1.55B | -$1.53B | -$1.51B | -$1.48B | -$1.48B |
| Less: Treasury Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| -Accumulated Depreciation | – | – | – | -$3.48M | -$3.48M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1.84M | -$1.93M | -$15.65M | -$166.78M | -$5.00M |
| Net cash flow from continuing operations | $1.84M | -$1.93M | -$15.65M | -$166.78M | -$5.00M |
| Net Income from Continuing Operations | -$13.90M | -$17.58M | -$30.37M | -$221.25M | -$21.15M |
| Gain/Loss from Continuing Operations | $0.00 | $0.00 | $829,000.00 | – | – |
| Depreciation & Depletion & Amortization | $120,000.00 | $114,000.00 | $110,000.00 | $633,000.00 | $128,000.00 |
| Other Non-Cash Items | $4.73M | $6.19M | $6.70M | $37.22M | $6.90M |
| Change in Working Capital | $4.05M | $2.63M | $1.55M | -$12.38M | $4.05M |
| -Change in Receivables | -$10.18M | -$16.70M | -$2.60M | -$39.33M | -$22.34M |
| -Change in Inventory | -$6.34M | -$3.96M | $665,000.00 | -$11.78M | $2.00M |
| -Change in Prepaid Assets | $81,000.00 | $132,000.00 | $6.92M | $5.51M | -$2.13M |
| -Change in Payables and Accrued Expense | $20.98M | $23.16M | -$3.28M | $34.23M | $27.64M |
| -Change in Other Current Assets | -$478,000.00 | $0.00 | -$171,000.00 | -$1.22M | -$1.22M |
| -Change In Other Working Capital | -$8,000.00 | -$5,000.00 | $10,000.00 | $222,000.00 | $90,000.00 |
| Net cash flow from investing | -$110,000.00 | -$44,000.00 | -$61,000.00 | -$229,000.00 | -$87,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$110,000.00 | -$44,000.00 | -$61,000.00 | -$229,000.00 | -$87,000.00 |
| Net PPE Purchase and Sale | -$110,000.00 | -$44,000.00 | -$61,000.00 | -$229,000.00 | -$87,000.00 |
| Financing Cash Flow | $351,000.00 | $3.55M | $66.64M | -$288,000.00 | -$97,000.00 |
| Net Cash Flow from Continuing Financing Activities | $351,000.00 | $3.55M | $66.64M | -$288,000.00 | -$97,000.00 |
| Net Issuance Payments Of Debt | $0.00 | $0.00 | -$55.80M | $0.00 | $0.00 |
| Net Common Stock Issuance | $0.00 | $0.00 | $121.97M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $372,000.00 | $3.55M | $591,000.00 | $1.64M | $1.27M |
| Net Other Financing Charges | -$21,000.00 | $0.00 | -$128,000.00 | -$1.93M | -$1.36M |
| Ending Cash Balance | $187.42M | $185.34M | $183.77M | $132.83M | $132.83M |
| Net Change in Cash | $2.08M | $1.58M | $50.93M | -$167.29M | -$5.19M |
| Beginning Cash Balance | $185.34M | $183.77M | $132.83M | $300.13M | $138.02M |
| Free Cash Flow | $1.73M | -$1.97M | -$15.71M | -$167.00M | -$5.09M |
No comments yet — be the first to weigh in on PHAT.
Sign in to join the discussion.